Elite control of HIV infection: implications for vaccine design (Summary) Print E-mail
Saturday, 18 July 2009 22:44

Background: ‘Elite controllers’ are rare HIV-infected individuals who are able to spontaneously control HIV replication without medication, maintaining viral loads that are consistently below the limits of detection by currently available commercial assays.

Objective: To examine studies of elite controllers that may elucidate mechanisms of HIV immune control useful in designing a vaccine.

Methods: Recent literature on HIV controllers and studies that have evaluated aspects of viral and host immunology that correlate with viral control are examined.

Results/conclusions: Although many elements of innate and adaptive immunity are associated with control of HIV infection, the specific mechanism(s) by which elite controllers achieve control remain undefined. Ongoing studies of elite controllers, including those examining host genetic polymorphisms, should facilitate the definition of an effective HIV-specific immune response and guide vaccine design.

  • Journal: Expert Opinion on Biological Therapy
  • Date: January 2009, Vol. 9, No. 1, Pages 55-69 , DOI 10.1517/14712590802571928
  • Summary Link: Expert Opinion
Del.icio.us     Digg This!     Facebook     Google     Reddit     Stumble It!
Last Updated ( Saturday, 18 July 2009 22:54 )

Please Donate!

Please make a tax deductible donation to Zephyr LTNP Foundation, a 501(c)(3) entity via Paypal. No Paypal account required.

CROI 2011

  • Wednesday 9th March 2011
    This is our final bulletin from CROI 2011. We hope you have found our news coverage useful. You can find all our coverage at www.aidsmap.com/croi2011, including the news reports and bulletins.We are always looking for ways of improving and developing our resources – so if you have any comments that you would like
  • Thursday 3rd March 2011
    There is increasing evidence of the transmission of HIV strains with resistance to anti-HIV drugs in low- and middle-income countries. Research in eleven sub-Saharan African countries showed that the chances of detecting transmitted resistance increased by over a third each year that a country had been scaling up HIV treatment. A separate study involving people recently diagnosed
  • Wednesday 2nd March 2011
    A new type of anti-HIV drug that targets the first step in HIV’s entry into cells has done well in a Phase IIa study. Currently known as BMS-663068, the drug was shown to be safe and to work against the virus. HIV cell entry is a three-step process. The virus must first attach to the

Follow Us

  • Facebook Page: zephyrfoundation.org
  • Twitter: zephyrfound
  • YouTube: zephyrfoundation

Controllers in Study

 Donation Thermometer
 Donation Thermometer
 Donation Thermometer

Our Goal:
December 30, 2009

Current Breakdown: 505 Elite Controllers 1009 Viremic Controllers 211 Other